ALGS Stock — Aligos Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections (e.g., SARS‑CoV‑2, SARS‑CoV, MERS‑CoV, and other related infections).

Source: 10-K FY2025 via SEC EDGAR

Share price

$4.07

Market cap

$25.4M

Cash

$31.1M

Enterprise value

-$5.7M

Balance sheet

Cash	$31.1M
Debt	$0.0M
Net cash	$31.1M
Enterprise value	-$5.7M
Basic shares	6.2M shares
Fully diluted shares	17.4M shares
Fully diluted market cap	$70.8M
Cash per share	$4.98
Quarterly burn	$24.9M
Cash runway	1.2 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

6.2M

Pre-funded warrants

4.2M

Options

2.1M

RSUs

0.1M

Warrants

4.2M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.5M

FDSO

17.4M

Cap table as of 2026-06-30.

Price history

Loading ALGS daily closes…

Loading price history…

Next catalyst

ALG-000184 · Apr 12 - May 24 in 5 mo · Phase 2 · Chronic Hepatitis B Infection

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Apr 12 - May 24 in 5 mo	ALG-000184	Phase 2	Chronic Hepatitis B Infection	late Q3 2027

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Pevifoscorvir sodium

Phase 2 · Active Modality: small molecule

Aliases ALG-000184

Target HBV capsid assembly (CAM-E)

Partnerships Xiamen Amoytop Biotech Co., Ltd: exclusive Greater China license, $25.0M upfront (net of tax, received Jul 2026), up to $420M in clinical/regulatory/sales milestones, tiered high single-digit royalties

Indications

Chronic HBV infection (Phase 2)

Catalysts

— late Q3 2027

Status note Phase 2 B-SUPREME study (NCT06963710, ~250 subjects, 48-week monotherapy vs tenofovir disoproxil fumarate) enrollment completed (131 HBeAg+ Part 1a, 114 HBeAg- Part 2a). Received FDA Fast Track Designation and China NMPA/CDE Breakthrough Therapy Designation for chronic HBV infection.

ALG-170675

Preclinical · Active Modality: antisense oligonucleotide (ASO)

Target HBV RNA transcripts (HBsAg mRNA); also TLR8 agonist activity

Partnerships Xiamen Amoytop Biotech Co., Ltd: research collaboration; Amoytop holds Greater China rights and funds China development; earned $3.0M milestone at IND-enabling start (Jan 2026) and $3.0M at China IND approval (Jul 2026); eligible for up to $109.0M in development/commercialization milestones plus tiered royalties

Indications

Chronic HBV infection (Preclinical)

Catalysts

— Q3 2026

Status note Next-generation ASO discovered under Amoytop collaboration. Amoytop received IND approval in China in July 2026; Phase 1 in healthy volunteers with planned HBV-infected cohort (following 150 mg MAD cohort, Q4 2026) to be sponsored and performed by Amoytop. Each party funds its own development; Aligos may run a Phase 2 in 2028.

ALG-055009

Phase 2 · Active Modality: small molecule

Target Thyroid hormone receptor beta (THR-beta)

Indications

Metabolic dysfunction-associated steatohepatitis (MASH) (Phase 2)
Obesity (Preclinical)

Status note Phase 2a HERALD study (2024) completed. Obesity work is preclinical (diet-induced obese mouse data for combination with incretin receptor agonists). Company is evaluating options to fund continued development, including potential out-licensing; not explicitly discontinued.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	ALG-000184
Lead indication	Chronic Hepatitis B Infection
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06963710	Phase 2	Active, not recruiting	Sponsor	Aligos Therapeutics	—	Chronic Hepatitis B Infection	late Q3 2027
NCT06672900	Phase 1	Active, not recruiting	Sponsor	Aligos Therapeutics	—	Healthy Volunteer	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Aligos Therapeutics on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	83,055	no change	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ALGS — Aligos Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

ALGS — Aligos Therapeutics Inc.